EA200802417A1 - SUBSTITUTED PHENYLACETIC ACIDS AS DP-2 ANTAGONISTS - Google Patents
SUBSTITUTED PHENYLACETIC ACIDS AS DP-2 ANTAGONISTSInfo
- Publication number
- EA200802417A1 EA200802417A1 EA200802417A EA200802417A EA200802417A1 EA 200802417 A1 EA200802417 A1 EA 200802417A1 EA 200802417 A EA200802417 A EA 200802417A EA 200802417 A EA200802417 A EA 200802417A EA 200802417 A1 EA200802417 A1 EA 200802417A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antagonists
- substituted phenylacetic
- phenylacetic acids
- methods
- conditions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Предложены замещенные производные фенилуксусной кислоты формулы (I), фармацевтические композиции, способы их получения и способы, которые являются полезными в лечении и предупреждении нарушений или состояний, чувствительных к модуляции DP-2-рецептора, в частности воспалительных и связанных с иммунитетом нарушений и состояний, таких как астма, аллергический ринит и атопический дерматит.Proposed substituted phenylacetic acid derivatives of formula (I), pharmaceutical compositions, methods for their preparation and methods that are useful in the treatment and prevention of disorders or conditions sensitive to modulation of the DP-2 receptor, in particular inflammatory and immune-related disorders and conditions, such as asthma, allergic rhinitis and atopic dermatitis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81239906P | 2006-06-09 | 2006-06-09 | |
PCT/US2007/070805 WO2007146838A2 (en) | 2006-06-09 | 2007-06-08 | Substituted phenyl acetic acids as dp-2 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200802417A1 true EA200802417A1 (en) | 2009-06-30 |
Family
ID=38819983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200802417A EA200802417A1 (en) | 2006-06-09 | 2007-06-08 | SUBSTITUTED PHENYLACETIC ACIDS AS DP-2 ANTAGONISTS |
EA201200423A EA201200423A1 (en) | 2006-06-09 | 2007-06-08 | SUBSTITUTED PHENYLACETIC ACIDS AS DP-2 ANTAGONISTS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201200423A EA201200423A1 (en) | 2006-06-09 | 2007-06-08 | SUBSTITUTED PHENYLACETIC ACIDS AS DP-2 ANTAGONISTS |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2044017A2 (en) |
JP (1) | JP2009539881A (en) |
CN (1) | CN101490001A (en) |
AU (1) | AU2007257841A1 (en) |
BR (1) | BRPI0712332A2 (en) |
CA (1) | CA2654927A1 (en) |
EA (2) | EA200802417A1 (en) |
MX (1) | MX2008015638A (en) |
NO (1) | NO20090139L (en) |
WO (1) | WO2007146838A2 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007034620A1 (en) * | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New B1 antagonists |
US8247610B2 (en) | 2007-10-19 | 2012-08-21 | Janssen Pharmaceutica N.V. | Amine linked modulators of γ-secretase |
BRPI0817433A2 (en) * | 2007-10-19 | 2015-06-16 | Janssen Pharmaceutica Nv | Piperidinyl and piperazinyl gamma secretase modulators |
CA2702959C (en) | 2007-10-19 | 2016-07-26 | Janssen Pharmaceutica Nv | Carbon linked modulators of .gamma.-secretase |
CN102596193A (en) * | 2009-07-31 | 2012-07-18 | 潘米拉制药公司 | Dermal formulations of DP2 receptor antagonists |
JP2013516475A (en) * | 2010-01-06 | 2013-05-13 | アミラ ファーマシューティカルズ,インク. | DP2 antagonists and uses thereof |
AU2011275417A1 (en) | 2010-07-05 | 2013-02-21 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
BR112013024267A2 (en) | 2011-03-22 | 2018-06-26 | Advinus Therapeutics Ltd | substituted fused tricyclic compounds, compositions and medical applications thereof. |
PL3409278T3 (en) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
JP6099149B2 (en) * | 2011-10-25 | 2017-03-22 | 塩野義製薬株式会社 | HIV replication inhibitor |
US8691993B2 (en) * | 2011-12-12 | 2014-04-08 | Hoffmann-La Roche Inc. | Piperidinyl naphthylacetic acids |
CA2858328A1 (en) | 2011-12-21 | 2013-06-27 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
JO3407B1 (en) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | Tetrahydropyrazolopyrimidine Compounds |
JP6127135B2 (en) | 2012-07-05 | 2017-05-10 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 1-Phenyl substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
JP6590226B2 (en) * | 2016-05-11 | 2019-10-16 | 株式会社シード探索研究所 | Oxaziridine compound and method for producing the same |
JP2020536863A (en) | 2017-10-06 | 2020-12-17 | フォーマ セラピューティクス,インコーポレイテッド | Ubiquitin-specific inhibition of peptidase 30 |
EP4218934A1 (en) | 2018-10-05 | 2023-08-02 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3991061A (en) * | 1975-07-16 | 1976-11-09 | G. D. Searle & Co. | Azanaphthaleneacetic acid derivatives |
WO1993012086A1 (en) * | 1991-12-11 | 1993-06-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivative |
ZA939516B (en) * | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
US7321001B2 (en) * | 2002-12-20 | 2008-01-22 | Amgen Inc. | Asthma and allergic inflammation modulators |
EA015358B1 (en) * | 2005-09-30 | 2011-06-30 | Пульмаджен Терапьютикс (Эсме) Лимитед | Quinolines and their therapeutic use |
GT200600457A (en) * | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | DIHYDROGEN PHOSPHATE SALT AS ANTAGONIST OF PROSTAGLANDINA D2 RECEPTOR |
-
2007
- 2007-06-08 BR BRPI0712332-9A patent/BRPI0712332A2/en not_active IP Right Cessation
- 2007-06-08 AU AU2007257841A patent/AU2007257841A1/en not_active Abandoned
- 2007-06-08 EA EA200802417A patent/EA200802417A1/en unknown
- 2007-06-08 JP JP2009514557A patent/JP2009539881A/en not_active Withdrawn
- 2007-06-08 EP EP07812087A patent/EP2044017A2/en not_active Withdrawn
- 2007-06-08 CN CNA2007800262835A patent/CN101490001A/en active Pending
- 2007-06-08 CA CA002654927A patent/CA2654927A1/en not_active Abandoned
- 2007-06-08 WO PCT/US2007/070805 patent/WO2007146838A2/en active Application Filing
- 2007-06-08 EA EA201200423A patent/EA201200423A1/en unknown
- 2007-06-08 MX MX2008015638A patent/MX2008015638A/en not_active Application Discontinuation
-
2009
- 2009-01-09 NO NO20090139A patent/NO20090139L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007146838A2 (en) | 2007-12-21 |
BRPI0712332A2 (en) | 2012-12-18 |
EA201200423A1 (en) | 2012-08-30 |
JP2009539881A (en) | 2009-11-19 |
CN101490001A (en) | 2009-07-22 |
AU2007257841A1 (en) | 2007-12-21 |
CA2654927A1 (en) | 2007-12-21 |
MX2008015638A (en) | 2009-01-09 |
WO2007146838A3 (en) | 2008-03-13 |
EP2044017A2 (en) | 2009-04-08 |
NO20090139L (en) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200802417A1 (en) | SUBSTITUTED PHENYLACETIC ACIDS AS DP-2 ANTAGONISTS | |
EA200802415A1 (en) | REPLACED PHENYLACETIC ACIDS AS A DP-2-ANTAGONIST | |
ATE538100T1 (en) | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | |
CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
WO2010018109A3 (en) | Substituted aminotetralines | |
EA201001821A1 (en) | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | |
ATE544767T1 (en) | TRIAZOLOA4,5-DÜPYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | |
WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
WO2009063215A3 (en) | Use of crth2 antagonist compounds | |
EA200870282A1 (en) | AMINE DERIVATIVES | |
NO20083427L (en) | Cystotoxic agents comprising novel tomaymycin derivatives and their therapeutic use | |
NO20090723L (en) | Condensed heterocyclic derivatives and methods of use | |
WO2013184876A8 (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
EA201171081A1 (en) | INDOL DERIVATIVES AS AN ANTAGONISTS OF CRTH2 RECEPTOR | |
NO20084418L (en) | Azolopyridin-3-one derivatives as inhibitors of endothelial lipase | |
UA100227C2 (en) | Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use | |
EA201490540A1 (en) | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | |
EA201070091A1 (en) | DERIVATIVES OF PIPERIDINE, SUITABLE AS ANTAGONISTS OF OREXIN RECEPTOR | |
NO20091489L (en) | Thiazole pyrazolopyridines as CRF1 receptor antagonists | |
WO2010031184A8 (en) | Azaindole derivatives as crth2 receptor antagonists | |
EA200801996A1 (en) | 2-SUBSTITUTED DERIVATIVES OF 4-BENZIL-PHTHALASINONES AS HISTAMINE H1-AND H3-ANTAGONISTS | |
MY165113A (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
WO2010018112A3 (en) | Monoaryl aminotetralines | |
WO2009132774A8 (en) | New substituted indolin-2-one derivatives and their use as p38 mitogen-activated kinase inhibitors | |
EA023861B3 (en) | Pyrrolidine carboxylic acid derivatives as agonists of g-protein coupled receptor 43 (gpr43), pharmaceutical composition and methods for use thereof in treating metabolic disorders |